AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05960110
Drug: Fluoride toothpaste
RxNorm normalized name: sodium fluoride Toothpaste
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride toothpaste 1450 ppm
Trial: NCT04535401
Drug: Elimusertib
RxNorm normalized name: Elimusertib
DrugBank: Elimusertib (DB19041)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04535401
Drug: Irinotecan Hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00002434
Drug: Trimetrexate glucuronate
RxNorm normalized name: Trimetrexate Glucuronate
DrugBank: Trimetrexate (DB01157)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05102396
Drug: Topical oxybutynin spray
RxNorm normalized name: oxybutynin Topical Gel
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive topical oxybutynin spray (10%).
Trial: NCT05102396
Drug: Oral oxybutynin
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive oxybutynin (tablets).
Trial: NCT05022030
Drug: mCapOX plus cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: capecitabine 1000mg/m2 po bid d1-7+oxaliplatin ivgtt 85mg/m2 d1+cetuximab ivgtt 500mg/m2, q2w
Trial: NCT05022030
Drug: mFOLFOX6 plus cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oxaliplatin ivgtt 85mg/m2 d1+ leucovorin ivgtt 400mg/m2 d1+ fluorouracil iv bolus 400mg/m2 d1+ fluorouracil 2400mg/m2 continuous infusion for 46h+cetuximab ivgtt 500mg/m2, q2w
Trial: NCT06553950
Drug: Botox injection
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Patients will be treated by Botox injection in lateral pterygoid muscle and medications like muscle relaxants, antidepressants and nonsteroidal anti-inflammatory drugs.~A Botox-A vial was diluted with normal saline to a concentration of 10 U per 0.1 mL for injection in a 1-ml insulin syringe. This will be injected into the ipsilateral lateral pterygoid muscle.
Trial: NCT06250894
Drug: PD-1inhibitor
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive 3 cycles of preoperative chemotherapy with Sintilimab（PD-1 inbibitor） and SOX (every 3 weeks), followed by radiotherapy (total dose of 36-40Gy in 18-22 fractions) during cycle 1 of the combination. Radical surgery for gastric cancer will be performed within 4-6 weeks after completion of neoadjuvant treatment, followed by 3-5 cycles of postoperative adjuvant chemotherapy with the SOX regimen.
Trial: NCT05258825
Drug: Monoferric
RxNorm normalized name: Monoferric
DrugBank: Ferric derisomaltose (DB15617)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single intravenous dose of 1000 mg of Monoferric will be administered to a patient 3-4 weeks before anticipated surgery.
Trial: NCT04564430
Drug: Catapresan
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention is either a single intravenous bolus of 3mcg/kg Catapresan (150mcg/1ml) or an equal amount of saline at the time of tourniquet inflation.
Trial: NCT05356741
Drug: pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered as IV infusion
Trial: NCT00000643
Drug: Pyrimethamine
RxNorm normalized name: Pyrimethamine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04400539
Drug: Nivolumab Injection
RxNorm normalized name: nivolumab Injection
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Seven to 10 days after VATS, patients will start to be treated by Nivolumab 240mg IV every 2 weeks till progression (CT-scan reassessment every 8 cycles), unacceptable toxicity, or maximum 2 years.
Trial: NCT05025735
Drug: Dapagliflozin 10Mg Tab
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Hyperglycemia is an expected effect of PI3K inhibitors given the pivotal role of PI3K in mediating the response to insulin in multiple tissues. Blocking insulin signaling by p110α inhibitors leads to glycogen breakdown in the liver along with decreased glucose uptake in peripheral tissues. The resulting hyperglycemia causes a compensatory response of increase insulin secretion by the pancreas.~If concurrent treatment with dapagliflozin can abrogate the alpelisib induced hyperglycemia and subsequent rebound hyperinsulinemia it may significantly improve the therapeutic efficacy of alpelisib.
Trial: NCT04928950
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated Charcoal, Powder, USP is carbon that has been treated to create low-volume pores that increase the area available for chemical reactions and adsorption. The most common pharmaceutical uses of activated charcoal is as a purification agent and antitoxin. All Spectrum Chemical USP products are manufactured, packaged and stored under current Good Manufacturing Practices (cGMP) per 21CFR part 211 in FDA registered and inspected facilities.
Trial: NCT05071729
Drug: Elinzanetant (BAY3427080)
RxNorm normalized name: Elinzanetant
DrugBank: Elinzanetant (DB18968)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of elinzanetant on Day 1.
Trial: NCT06048926
Drug: Carrelizumab
RxNorm normalized name: CERTOLIZUMAB
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg/time, iv, Q3W
Trial: NCT06048926
Drug: Paclitaxel injection
RxNorm normalized name: paclitaxel Injection
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 50mg/m2,iv, D1, 8, 15, 22, 29, once a week, a total of 5 times
Trial: NCT06048926
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg/m2，iv， D1、8、15、22、29，once a week, a total of 5 times
Trial: NCT05987345
Drug: Anti-PD-1 monoclonal antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 monoclonal antibody administered on Day 7 then routinely.
Trial: NCT04735965
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine would be intravenously infused at a dose of 1μg/kg over 15 minutes 30 min before the end of surgery
Trial: NCT04735965
Drug: Meperidine
RxNorm normalized name: Meperidine
DrugBank: Meperidine (DB00454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine would be intravenously injected at a dose of 0.5mg/kg 30 min before the end of surgery
Trial: NCT06387901
Drug: Paclitaxel Chemotherapy
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive paclitaxel, a taxane chemotherapeutic agent used in the treatment of breast cancer. The administration involves an intravenous infusion of paclitaxel at a dosage of 80 mg/m². The treatment is scheduled once a week, continuing for a total duration of 12 weeks. This regimen is part of a (neo-)adjuvant therapy for female patients diagnosed with stage II or III breast cancer. The intervention aims to assess the pharmacokinetics of paclitaxel in relation to patient body composition and physical activity, evaluating its impact on dose-limiting toxicities and overall treatment efficacy.
Trial: NCT04899349
Drug: Alpelisib
RxNorm normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alpelisib (tablets) administered at 300mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 8 in a 28 days cycle.
Trial: NCT04899349
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant (prefilled syringe) 500mg administered intramuscularly at Cycle 1 Day 1 and 15 after randomization and then at Day 1 of each subsequent cycle during the randomized treatment phase.
Trial: NCT04899349
Drug: Metformin XR
RxNorm normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin XR (tablets) administered at a starting dose of 500mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 500 mg once a day to 2000 mg once a day.
Trial: NCT04899349
Drug: Dapagliflozin + metformin XR
RxNorm normalized name: dapagliflozin / metformin Extended Release Oral Tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dapagliflozin + metformin XR administered as a single tablet combination at a starting dose of 5 mg dapagliflozin + 500 mg metformin XR orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 5 mg dapagliflozin + 500 mg metformin XR orally once daily to 10 mg dapagliflozin + 2000 mg metformin XR once daily
Trial: NCT04899349
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin (tablet) at a starting dose of 5mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 days cycle. Dose titration from 5 mg to 10 mg once daily
Trial: NCT06565507
Drug: Oxfendazole single dose
RxNorm normalized name: Oxfendazole
DrugBank: Oxfendazole (DB11446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive active oxfendazole, 20 mg/kg/day, orally, as a single dose. Oxfendazole placebo will be used at days 4 and 7 to maintain blinding between the two intervention arms.
Trial: NCT06565507
Drug: Oxfendazole three doses
RxNorm normalized name: Oxfendazole
DrugBank: Oxfendazole (DB11446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive active oxfendazole, 20 mg/kg/day, orally, in three days (1, 4 and 7)
Trial: NCT06565507
Drug: albendazole plus praziquantel regime
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive a combination of albendazole plus praziquantel, as a standard treatment for brain cysticercosis (neurocysticercosis), orally, for ten days. Albendazole will be given at 15/kg/d and praziquantel at 50/kg/d.
Trial: NCT04961099
Drug: HY01
RxNorm normalized name: Hydralazine
DrugBank: Hydralazine (DB01275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: low-dose group: HY01 10mg（20mg/ml）, administrated on D1, D4 and D7 high-dose group: HY01 20mg（40mg/ml）, administrated on D1, D4 and D7
Trial: NCT06056349
Drug: Midazolam oral solution
RxNorm normalized name: midazolam Oral Solution
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Buccal administration
Trial: NCT06056349
Drug: ClonazePAM Oral Product
RxNorm normalized name: clonazepam Oral Product
DrugBank: Clonazepam (DB01068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orodispersable
Trial: NCT06108349
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol (CBD) is a non-psychoactive minor cannabinoid component of Cannabis sativa that is emerging as a treatment to mitigate pain, numbness, and tingling associated with peripheral neuropathy. CBD acts through multiple receptors to modulate central and peripheral neuropathic signaling pathways to alleviate pain.
Trial: NCT06179030
Drug: dexamethasone implant versus ranibizumab
RxNorm normalized name: dexamethasone Drug Implant
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexamethasone implant versus ranibizumab will be studied as a secondary outcome
Trial: NCT03014440
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04521335
Drug: Copper Gluconate
RxNorm normalized name: Copper Gluconate
DrugBank: Copper gluconate (DB11246)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be instructed to self-administer disulfiram and copper gluconate twice daily at the assigned dose level. Both medications will be administered in 28-day cycles.
Trial: NCT06441110
Drug: Tislelizumab in Combination with Bacillus Calmette-Guérin
RxNorm normalized name: BACILLUS CALMETTE-GUERIN,TICE VACCINE
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative immediate instillation of epirubicin (50mg) is administered. Postoperatively, 200mg of tislelizumab injection is given intravenously every 3 weeks, with each 21-day period constituting one cycle. The medication is administered on day 1 of each cycle, continuing for one year. Eligible patients for the single-arm group (N = 76) begin BCG instillation after 2 weeks, with a dosage of 120mg per instillation, totaling 19 instillations: this starts with a 6-week induction phase of weekly BCG instillations, followed by BCG instillations every 2 weeks for three consecutive times; thereafter, maintenance instillation therapy commences, involving monthly BCG instillations for a total of ten times.
Trial: NCT05146674
Drug: Tadalafil 5mg
RxNorm normalized name: TADALAFIL 5MG TAB
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Our prospective, randomized, study will consist of a 1-week baseline period and 12-week double-blind treatment period During the baseline period, patients' characteristics, including medical and sexual history, physical examination results, vital signs, HPMDQ score, IPSS, International Index of Erectile Function (IIEF) score, PMD volume, and uroflowmetry results; and laboratory results, including urine analysis results, will be recorded.~After the baseline period, patients will be randomly assigned, 1:1, to the treatment or control groups using a computer-generated system. Both study groups will be advised to do bulbar urethral massage in addition to pelvic floor muscle exercise (explained later) during the study period, treatment group will be given tadalafil 5 mg (treatment group) daily or no medication (control group).
Trial: NCT04900038
Drug: Dolutegravir
RxNorm normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: DTG was available as 50 mg tablets administered orally.
Trial: NCT04900038
Drug: Lamivudine capsules
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3TC was available as 300 mg capsules administered orally as a blinded treatment.
Trial: NCT04900038
Drug: Lamivudine tablets
RxNorm normalized name: Lamivudine Tablets
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3TC was available as 300 mg tablets administered orally as an unblinded treatment.
Trial: NCT05080959
Drug: CPL-01
RxNorm normalized name: anti-inhibitor coagulant complex
DrugBank: Anti-inhibitor coagulant complex (DB13151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single dose
Trial: NCT05114213
Drug: SOC chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The chemotherapy is given according to current standard of care, consisting of in minimum doublet - chemotherapy and excluding monotherapy regimens.
Trial: NCT04405596
Drug: Ambroxol Hydrochloride
RxNorm normalized name: AMBROXOL HYDROCHLORIDE
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment regimen consists of a titration phase and a maintenance phase. Participants begin the titration phase (Weeks 1 and 2) taking 6 capsules a day (450mg or 0 mg) divided BID (3 capsules in the morning and 3 capsules in the evening). The first medication dose will be taken at the end of Baseline visit and in the presence of the study Neurologist. Possible side effects will be observed for 30 minutes. Medication dose will increase bi-weekly to 12 capsules on Weeks 3 and 4, and 18 capsules on Weeks 5 and 6 divided BID. At the end of titration (Week 5) participants will have reached a maximum of 1350mg or 0mg per day, depending on group allocation. In the maintenance phase, participants will remain in their maximum dose (1350mg or 0mg) from Week 5 to Week 52 (End of Trial).
Trial: NCT05233982
Drug: Olaparib Oral Product
RxNorm normalized name: olaparib Oral Product
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib Maintenace Treatment after first line platium based chemotherapy in BRCA wilde-type ovarian cancer patients
Trial: NCT05228600
Drug: YL-13027
RxNorm normalized name: dibenzothiazol-2-yl disulfide
DrugBank: 2,2'-Dibenzothiazyl disulfide (DB14201)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YL-13027 is a novel small molecule TGF-βR1 inhibitor. 1.1.1. Chemical Properties~Chemical Name:~6-(5-fluoro-2-(6-methylpyridin-2-yl)phenyl)imidazo\[1,2-a\]pyridine-3-carboxamide Molecular Formula C20H15FN4O Molecular Weight 346.36 Formulation YL-13027 is provided as pink film coated tablets for oral administration in two strengths, 30 mg and 120 mg.~Packaging and Storage YL-13027 tablets are packaged (30 tablets/bottle) in the 45 mL opaque HDPE bottles with child resistant polypropylene caps, induction-sealed inner polypropylene liners. YL-13027 tablets should be protected from light in a closed container and stored at room temperature.~Stability The shelf-life of YL-13027 oral tablets is tentatively set at 24 months when stored at room temperature.
Trial: NCT06258967
Drug: ciprofol
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive ciprofol as general anesthesia induction drug, using the titrated anesthesia method.
Trial: NCT06258967
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive propofol as general anesthesia induction drug, using the titrated anesthesia method.
Trial: NCT04933747
Drug: Iberdomide
RxNorm normalized name: Iberdomide
DrugBank: Iberdomide (DB12101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a single oral dose of 1mg iberdomide in participants
Trial: NCT04933747
Drug: Iberdomide
RxNorm normalized name: Iberdomide
DrugBank: Iberdomide (DB12101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of a single oral dose of 1mg iberdomide in participants on 2 occasions - once on a dialysis day and once on a non-dialysis day
Trial: NCT06350565
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This clinical study will plan to enrol 24 Chinese pregnant subjects with 34+0-35+6GW preterm preterm labour requiring dexamethasone treatment and 24 pregnant women with 34+0-38+6GW preterm preterm labour and a diagnosis of gestational diabetes mellitus (GDM) or diabetes mellitus in combination with pregnancy, each of them randomly divided into 2 groups requiring 4 doses of dexamethasone intramuscularly (half-dose of 2.5 mg, normal dose of 5 mg) for two days as well as two active blood acquisitions. During the recruitment and screening phase, the purpose of the trial, the study protocol, and the trial procedure were described in detail so that the subjects were fully informed and participated voluntarily, and the compliance of the subjects in the conduct of the trial was improved.
Trial: NCT05298644
Drug: Active Comparator
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menactra, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine.
Trial: NCT06060691
Drug: Kaempferol
RxNorm normalized name: 3'-HYDROXYKAEMPFEROL
DrugBank: Quercetin (DB04216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kaempferol
Trial: NCT05579860
Drug: Olezarsen
RxNorm normalized name: Olezarsen
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olezarsen will be administered by SC injection.
Trial: NCT06411457
Drug: SHR-A1811+Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assess the efficacy and safety of the SHR-A1811 in combination with Adebrelimab regimen in HER2 low-expressing metastatic breast cancer SHR-A1811 : 6.4mg/kg , q3w，d1, ivgtt Adebrelimab : 1200mg, q3w，d1, ivgtt
Trial: NCT00123149
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03786237
Drug: Rigosertib Oral Capsules / Rigosertib Intravenous
DrugBank: Rigosertib (DB12146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take Rigosertib either as oral capsules or will get intravenous infusions depending on the needs of the patients.~Oral Capsules:~Patients will take oral Rigosertib continuously for a total of three weeks, every four week cycle (three weeks on, one week off drug) for up to 13 cycles. Patients will take 560 mg of oral Rigosertib (ie, 2 capsules of 280 mg) in the morning and in the afternoon, total of 1120mg/day.~Intravenous Infusions:~For IV treatment Rigosertib 1800 mg/24 hr is diluted in 0.9% sodium chloride for injection just prior to dosing and is administered as a 72-hr CIV infusion on days 1, 2, and 3 of a 2-week cycle for the first eight 2-week cycles, then on days 1, 2, and 3 of a 4-week cycle thereafter.
Trial: NCT05429554
Drug: Vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: observe the effect of vildagliptin on cognitive function and cardiovascular in diabetic patients
Trial: NCT04883658
Drug: CKD-348(2)
RxNorm normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO
Trial: NCT05414370
Drug: Liquid oxygen
RxNorm normalized name: OXYGEN 99 L in 100 L RESPIRATORY (INHALATION) GAS [Liquid Oxygen]
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liquid medical oxygen will be administered for 6 hours using high-flow nasal cannula delivery system with an Fi02 of 100% and flow rate of 60 litres per minute.
Trial: NCT05414370
Drug: medical air
RxNorm normalized name: Medical air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic medical air will be administered for 6 hours using high-flow nasal cannula delivery system with a flow rate of 60 litres per minute.